Sanofi Terminates $375M Metabolex Diabetes Deal

Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment.

French pharma company Sanofi-Aventis has decided to terminate a deal with Metabolex that was worth up to $375 million in milestone payments. Less than a year ago Sanofi agreed to collaborate on MBX-2982, an orally active GPR119 agonist for the treatment of Type 2 diabetes.

An SEC filing didn't reveal the reason behind Sanofi's decision, and Metabolex spokesperson Don Hill told the San Francisco Business Times that Phase IIa data revealed no major concerns related to the drug's safety or efficacy. But Sanofi still chose to walk away after seeing

Related News

News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals

Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.

23 May 2024
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera

ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion.

1 May 2024
News First offers for pharma from Medicare drug price negotiations

Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.

5 Apr 2024
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market

In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...

20 Mar 2024
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote

On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya...

19 Mar 2024
News Pfizer maps out plans for developing new oncology therapeutics by 2030

Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023.

7 Mar 2024
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval

Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.

28 Feb 2024
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations

In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...

12 Feb 2024

CPHI Online is the largest global marketplace in the pharma ingredients industry

Sanofi Terminates $375M Metabolex Diabetes Deal

Related News

Position your company at the heart of the global Pharma industry with a CPHI Online membership

Request for general information

Send a message to Please review your profile details to ensure it is up-to-date.

Send a message to
Please review your profile details to ensure it is up-to-date.